These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1242657)

  • 41. [On the question of relationship between chemical structure and dermatotropic effect of some aromatic hydrocarbons induced in a biological model (author's transl)].
    Miglierini K; Sak M; Hegyi E
    Cesk Dermatol; 1976 Oct; 51(5):300-5. PubMed ID: 1000636
    [No Abstract]   [Full Text] [Related]  

  • 42. Arylpiperazines with N-acylated amino acids as 5-HT1A receptor ligands.
    Zajdel P; Subra G; Bojarski AJ; Duszyńska B; Pawłowski M; Martinez J
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3406-10. PubMed ID: 16677812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tissue response as a functional discriminator of receptor heterogeneity: effects of mixed receptor populations on Schild regressions.
    Kenakin TP
    Mol Pharmacol; 1992 Apr; 41(4):699-707. PubMed ID: 1569922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacological correction of work capacity in simulation studies].
    Shashkov VS; Lakota NG
    Farmakol Toksikol; 1984; 47(2):5-15. PubMed ID: 6714404
    [No Abstract]   [Full Text] [Related]  

  • 45. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
    Mager DE
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short linear cationic antimicrobial peptides: screening, optimizing, and prediction.
    Hilpert K; Fjell CD; Cherkasov A
    Methods Mol Biol; 2008; 494():127-59. PubMed ID: 18726572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Analysis of the role of various factors of the initial status of the body in the analgesic action of promedol].
    Dmitriev AV; Bershadskiĭ BG
    Farmakol Toksikol; 1984; 47(4):34-6. PubMed ID: 6479310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The relation between Ames test data and electronic structure for a series of benzidine derivatives investigated by using cluster analysis.
    Imamura A; Tani S; Taketoshi M; Danzuka T
    Jpn J Cancer Res; 1985 Oct; 76(10):937-45. PubMed ID: 3935625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Supervised self-organizing maps in drug discovery. 2. Improvements in descriptor selection and model validation.
    Xiao YD; Harris R; Bayram E; Ii PS; Schmitt JD
    J Chem Inf Model; 2006; 46(1):137-44. PubMed ID: 16426050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor.
    de Graaf C; Rognan D
    J Med Chem; 2008 Aug; 51(16):4978-85. PubMed ID: 18680279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A quantitative structure-activity analysis based on quantum statistical derivations].
    Schwarz G; Barth A
    Pharmazie; 1975 Dec; 30(12):805-6. PubMed ID: 1219804
    [No Abstract]   [Full Text] [Related]  

  • 52. [Falsely positive values in multi-channel analysis: an estimation of their frequency with Sylvester's formula and their reduction by a multivariate test quantity (author's transl)].
    Rehpenning W; Harm K; Domesle A; Voigt KD
    J Clin Chem Clin Biochem; 1979 Sep; 17(9):565-72. PubMed ID: 501303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Structure and biological properties of lectins (author's transl)].
    Krop-Watorek A
    Postepy Biochem; 1978; 24(2):221-41. PubMed ID: 693438
    [No Abstract]   [Full Text] [Related]  

  • 54. On the use of indicator variables for studying the time-dependence of parameters in a response-time model.
    Brown CC
    Biometrics; 1975 Dec; 31(4):863-72. PubMed ID: 1203428
    [No Abstract]   [Full Text] [Related]  

  • 55. Application of the pharmacological screening process.
    Algate DR
    Drug Metab Rev; 1990; 22(6-8):809-20. PubMed ID: 2102459
    [No Abstract]   [Full Text] [Related]  

  • 56. Theoretical approaches to drug design and biological activity: critical comments to the use of mathematical methods applied to univariate and multivariate quantitative structure-activity relationships (QSAR).
    Mager PP
    Med Res Rev; 1982; 2(1):93-121. PubMed ID: 7109783
    [No Abstract]   [Full Text] [Related]  

  • 57. [Sense and nonsense of combination therapy].
    Otten H
    Med Welt; 1976 Sep; 27(36):1695-9. PubMed ID: 966984
    [No Abstract]   [Full Text] [Related]  

  • 58. [Use of regression analysis in the quantitative evaluation of the activity of biological preparations].
    Kheĭfets LB; Feofanova TV
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Aug; (8):96-102. PubMed ID: 1202888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Regression analysis of structure-activity relationships (Hansch-analysis)].
    Druckrey E
    Pharm Unserer Zeit; 1975 Sep; 4(5):145-50. PubMed ID: 1181596
    [No Abstract]   [Full Text] [Related]  

  • 60. Statistical analysis of structure-activity relationships.
    Daniels KL; Goyert JC; Strand RH; Farrell MP
    Fundam Appl Toxicol; 1983; 3(5):350-2. PubMed ID: 6642099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.